KOSDAQBiotech & Pharma059210

Metabiomed

₩3,200▲ 9.03%2026-11-18 close
Market Cap
₩86.9B
Turnover
₩700M
Volume
210K
Shares out.
27.2M
PER
7.1×
PBR
0.6×
EPS
₩409
Dividend Yield
3.63%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩105 per share · Prices as of the 2026-11-18 close

01

Report overview

Q3 Net Loss Puts New Business Profitability to the Test

Operating margin rose to 20.8% in 2025, but a net loss attributable to controlling shareholders of KRW 1.45 billion in the third quarter of 2026 has put the profitability of the new businesses in focus.

  1. 1

    Operating profit grew from KRW 5.34 billion in 2022 to KRW 21.4 billion in 2025, and the operating margin rose from 7.7% to 20.8%.

  2. 2

    Third-quarter 2026 operating profit fell 60.9% year on year to KRW 1.99 billion, and the company swung to a net loss attributable to controlling shareholders of KRW 1.45 billion.

  3. 3

    The new businesses remain small: in the second quarter of 2026 the medical division booked KRW 1.4 billion in sales (up 49.1%) and the cosmetics division KRW 1.3 billion (up 22.4%).

  4. 4

    Compared with the 2025 sales base of KRW 103 billion, the 2030 sales target of KRW 500 billion requires roughly five times the growth.

  5. 5

    Shareholder returns have expanded through a higher year-end dividend, a newly adopted interim dividend and treasury share cancellation.

02

Business structure

Metabiomed was founded in 1990 to make and sell dental materials and listed on KOSDAQ in 2008. The business runs on three axes: dental products, sutures, and new medical and cosmetic businesses built on its biopolymer materials.

According to a Korea Credit News report, the dental division accounted for KRW 49.9 billion (48.5%) of 2025 sales of KRW 103 billion, and the suture division for KRW 44.1 billion (42.8%).

In the first half of 2026, dental sales reached KRW 14.3 billion, up 25.9% year on year, while suture sales fell 17.7% to KRW 9.9 billion, according to a company announcement on August 18, 2026.

The new businesses remain small: in the second quarter of 2026 the medical division booked KRW 1.4 billion in sales and the cosmetics division KRW 1.3 billion, and the two combined rose 34.7% year on year to KRW 2.7 billion.

Sutures are mainly bioabsorbable products, while the dental side centers on root canal filling materials, and a dental resin material, Jet Flow Bulk, received US FDA approval in October 2024.

On competition, the suture market faces a shift toward synthetic absorbable sutures and rising rivalry, while the dental division benefits from demand for implants and bone grafts tied to population aging.

The new businesses use the biopolymer platform to extend into lifting threads, fillers, skin boosters and medical devices, and an anchor product for sports medicine has entered the orthopedic line-up.

Exports are the core, with the export share cited at 88.9% in a 2025 report, supported by sales offices in the United States, Germany, China and Japan and a production unit in Vietnam.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩23.5B₩5.1B21.6%
2025Q4₩26.2B₩2.9B11.2%
2026Q1₩24.4B₩4.9B19.9%
2026Q2₩27B₩6.3B23.2%
2026Q3₩24.7B₩2B8.1%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩68.9B₩5.3B₩2.6B7.7%4.3%90.8%
2023₩83.1B₩10.7B₩10.1B12.9%14.4%79.1%
2024₩94B₩17.2B₩22.4B18.3%24.0%84.5%
2025₩103B₩21.4B₩11B20.8%8.8%49.4%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a DART-filed annual basis, sales rose from KRW 68.9 billion in 2022 to KRW 83.1 billion in 2023 (up 20.5%), KRW 94 billion in 2024 (up 13.2%) and KRW 103 billion in 2025 (up 9.5%).

Sales have increased for three consecutive years from 2023 through 2025, with 2025 the largest year and 2022 the smallest in the 2022–2025 period.

Operating profit went from KRW 5.34 billion in 2022 to KRW 10.7 billion in 2023 (up 101.4%), KRW 17.2 billion in 2024 (up 60.2%) and KRW 21.4 billion in 2025 (up 24.4%), and the operating margin climbed from 7.7% to 20.8%.

As sales growth slowed, the margin gain carried profit growth, and one brokerage attributed this to higher sales of high value-added products and better production efficiency.

Profit attributable to controlling shareholders rose from KRW 2.63 billion in 2022 to KRW 10.1 billion in 2023 (up 283.6%) and KRW 22.4 billion in 2024 (up 122.2%), then fell 51.0% to KRW 11 billion in 2025.

The company cited non-operating valuation losses as the main reason for the lower net profit in 2025: a KRW 5.7 billion convertible bond valuation gain in 2024 became a KRW 7 billion valuation loss in 2025, and foreign currency translation gains above KRW 3 billion recorded in 2024 did not recur.

Net profit including non-controlling interests was KRW 10.8 billion in 2025, a different figure from profit attributable to controlling shareholders. Operating cash flow was KRW 9.16 billion in 2022, KRW 10.2 billion in 2023, KRW 22.6 billion in 2024 and KRW 19.8 billion in 2025.

At the end of 2025, total equity was KRW 124.9 billion, of which KRW 124.3 billion belonged to controlling shareholders, total liabilities were KRW 61.7 billion, and the debt ratio had fallen from 90.8% in 2022 to 49.4% in 2025.

Quarterly sales moved from KRW 23.5 billion in the third quarter of 2025 to KRW 26.2 billion in the fourth quarter (up 11.5% quarter on quarter), while operating profit fell from KRW 5.08 billion to KRW 2.94 billion (down 42.2%).

In the first quarter of 2026 sales were KRW 24.4 billion (down 6.9%) with operating profit of KRW 4.85 billion (up 65.1%), and in the second quarter sales rose to KRW 27 billion (up 10.5%) with operating profit of KRW 6.27 billion (up 29.2%).

In the third quarter of 2026 sales were KRW 24.7 billion (down 8.6% quarter on quarter, up 4.8% year on year) and operating profit was KRW 1.99 billion (down 68.3% quarter on quarter, down 60.9% year on year).

Profit attributable to controlling shareholders swung from KRW 4.46 billion in the third quarter of 2025 to a net loss of KRW 1.45 billion in the third quarter of 2026.

Over the last four quarters, from the fourth quarter of 2025 through the third quarter of 2026, profit attributable to controlling shareholders totaled KRW 1.11 billion. The divisional causes of the third-quarter operating profit decline are a point to confirm in the next periodic report.

05

Industry analysis

In sutures, a supply shortage that has not kept pace with demand is cited as a supportive factor. A September 2025 brokerage report said the ongoing supply chain shortage would benefit the suture division.

In contrast, the first-half 2026 figures showed that the shift toward synthetic absorbable sutures and rising competition reduced suture division sales and operating profit. Supply-side tailwinds and product-shift and competition headwinds therefore coexist.

On production, an August 2025 analysis reported that average utilization of suture production lines had exceeded 94%, making the shortage tangible.

The dental market benefits from rising demand for implants and bone grafts as the population ages, but the same analysis noted that dental capacity is already fully utilized, limiting further sales growth.

In aesthetics and biopolymer materials, fillers and lifting products made from bioabsorbable materials such as PDO and PLA are cited as growth avenues. The September 2025 report expected profitability in the materials business to exceed the current operating margin because few global competitors operate in the space.

Relative to peers, the company's position rests on proprietary technology accumulated in dental materials and sutures, which it is applying to new businesses.

06

Outlook

The company has set a 2030 target of KRW 500 billion in sales and KRW 1 trillion in enterprise value, announced in August 2026. Its target divisional mix is 29.4% dental, 22.2% sutures, 19.6% biopolymers, 23.4% cosmetics and 5.4% medical devices, with new growth businesses lifted to roughly 50% or more of sales.

To achieve this, the company plans to use its Osong materials innovation center for in-house biopolymer raw materials and independent production of filler and aesthetic materials.

Capital investment starts with production capacity coming online in 2026, a dedicated cosmetics production system by 2028, and a roadmap that considers additional investment in 2030.

The materials innovation center is slated to begin full operation in the second half of 2026, and the company has said it will start mass production of biopolymer materials in 2027.

The company also stated in August 2026 that its medical and aesthetic businesses alone would post sales well above KRW 10 billion this year. A biocompatible polymer filler is in preparation as a new business, and the anchor product is widening the orthopedic line-up.

Part of the shares bought in 2026 will be granted to employees as performance rewards and then cancelled by year-end. These are company targets, so progress will need to be checked against quarterly and annual results from 2027 onward.

The timing of biopolymer mass production and whether the new-business share of sales tracks the target path are the key points to confirm.

07

Valuation

PER
7.1×
PBR
0.6×
ROE
9.0%
EPS
₩409
BPS
₩4,718
Dividend per share
₩105

Multiples need to be read alongside earnings volatility. In November 2025 Yuanjin Securities analyzed the stock as trading at a large discount to the average of comparable domestic companies, a comparison based on 2025 earnings forecasts.

After the swing to a net loss in the third quarter of 2026, multiples based on earnings may be interpreted differently. Profit attributable to controlling shareholders fell from KRW 22.4 billion in 2024 to KRW 11 billion in 2025, and the last four quarters totaled KRW 1.11 billion.

When earnings decline, the earnings multiple rises at the same share price. Equity attributable to controlling shareholders reached KRW 124.3 billion at the end of 2025, so the premium to book value should be read together with earnings.

The company raised its year-end dividend from the 2024 level and introduced an interim dividend, so the direction of shareholder returns is expanding. If share cancellations continue through year-end, the change in shares outstanding will affect per-share comparisons.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Structural margin improvement

The operating margin rose from 7.7% in 2022 to 20.8% in 2025, and the second-quarter 2026 margin reached 23.2%, above 19.9% in the first quarter, according to the company. Gross margin also edged up to 57.2% from 53.1%, which the company attributed to higher sales of high value-added products and cost reductions. Profit growth continued even as sales growth slowed, and this is cited as the core strength.

Suture supply environment and capacity expansion

A September 2025 brokerage report said the supply chain shortage in sutures was continuing. Average utilization of suture production lines exceeded 94%, and the company has been building a second plant in Osong, an investment of about KRW 7 billion. A 2025 report cited an export share of 88.9%. Whether the added capacity converts into sales as overseas demand grows is the key test.

New businesses and wider shareholder returns

The medical and cosmetics divisions together posted KRW 2.7 billion in sales in the second quarter of 2026, up 34.7% year on year. The company has set a 2030 target of KRW 500 billion in sales and KRW 1 trillion in enterprise value.

Shareholder returns expanded through a higher year-end dividend for 2025 than for 2024, a new interim dividend provision and an interim dividend paid in June 2026. Treasury shares were also retired through earnings-funded cancellation in March 2026.

09

Bear factors

Swing to a net loss in Q3 2026

Third-quarter 2026 sales were KRW 24.7 billion, down 8.6% quarter on quarter, and operating profit was KRW 1.99 billion, down 60.9% year on year. Profit attributable to controlling shareholders moved from KRW 4.46 billion in the third quarter of 2025 to a net loss of KRW 1.45 billion.

As quarterly profit swings widen, the durability of the KRW 1.11 billion total over the last four quarters becomes harder to read.

Decline in suture sales

Suture division sales in the first half of 2026 were KRW 9.9 billion, down 17.7% year on year. The shift toward synthetic absorbable sutures and intensifying competition were cited as reasons for lower sales and operating profit. Sutures accounted for 42.8% of 2025 sales, so a decline in this division feeds directly into total results.

Earnings volatility and valuation gains and losses

Profit attributable to controlling shareholders fell 51.0% from KRW 22.4 billion in 2024 to KRW 11 billion in 2025. According to the company's filing, a convertible bond valuation gain of KRW 5.7 billion in 2024 became a valuation loss of KRW 7 billion in 2025.

Non-operating valuation items unrelated to operating performance can move net profit substantially, which is a weakness in the earnings profile.

10

Risk factors

Unproven profitability of new businesses

The medical and cosmetics divisions together generated about KRW 2.7 billion in sales in the second quarter of 2026, an early stage. The 2030 target of KRW 500 billion requires growth of roughly five times the 2025 base of KRW 103 billion. Whether biopolymer mass production timing and cost reductions line up is the point to confirm.

Financial and accounting volatility

Net profit in 2025 was affected by non-operating valuation items. The company explained that a rise in its share price led to a derivative valuation loss on convertible bonds, according to its March 2026 filing.

With quarterly operating profit swinging as widely as KRW 1.99 billion in the third quarter of 2026, non-operating items can push net profit into a loss.

Export dependence, currency and supply competition

The export share was cited at 88.9% in a 2025 report, so the company is highly exposed to currency movements and overseas customer demand. Currency gains above KRW 3 billion were recorded in 2024 when the won weakened, but no such gains occurred in 2025. The shift toward synthetic absorbable sutures and rising competition add pressure on suture volumes and prices.

11

What to watch next

  1. Late December 2026

    Part of the treasury shares acquired in 2026 will be granted to employees as performance rewards and the rest cancelled by year-end. Completion of the cancellation will show up as a change in shares outstanding.

  2. Second half of 2026 (materials innovation center start-up)

    Confirm whether the Osong materials innovation center reaches full operation in the second half of 2026. The company has said the center will support the start of biopolymer material mass production in 2027.

  3. March 2027

    The 2026 annual report, due by the end of March 2027, will show full-year 2026 results, the fourth-quarter figures and the divisional causes of the third-quarter operating profit decline.

  4. Mid-August 2027

    The first-half 2027 semi-annual report will show the sales share of the medical and cosmetics divisions and progress against the 2030 target path.

12

Overall view

Metabiomed has grown sales and operating profit since 2022, with the operating margin rising from 7.7% to 20.8%. The debt ratio fell to 49.4% at the end of 2025, and total equity stood at KRW 124.9 billion.

In the third quarter of 2026, however, sales fell to KRW 24.7 billion and operating profit to KRW 1.99 billion, and the company swung to a net loss attributable to controlling shareholders of KRW 1.45 billion.

Whether the margin recovery seen through the second quarter of 2026 was interrupted for divisional reasons is a question for the next periodic filings.

Supportive factors include the suture supply environment, a richer high value-added product mix and wider shareholder returns, while the weaker factors are falling suture sales, the third-quarter loss and net profit volatility from convertible bond valuations.

The new businesses generated about KRW 2.7 billion in combined sales in the second quarter of 2026, a long way from the 2030 target of KRW 500 billion.

The next checkpoints are the completion of share cancellations by year-end 2026, the start of biopolymer mass production in 2027 and the full-year results in the 2026 annual report due in March 2027. Earnings-based multiples are sensitive to swings in profit, so they should be read alongside the quarterly trend.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. mt.co.kr
  2. view.asiae.co.kr
  3. supple.kr
  4. hankyung.com
  5. thevc.kr
  6. creditnews.kr
  7. comp.wisereport.co.kr
  8. m.news.nate.com
  9. core.asiae.co.kr
  10. biotimes.co.kr
  11. vegannews.co.kr
  12. comp.fnguide.com
  13. newspim.com
  14. eugenefn.com
  15. m.irgo.co.kr
  16. hanaw.com
  17. view.asiae.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis